Not independent
Tenure on this board
7.5 yrs
Meeting calendar
CCRN · Annual meeting · Tuesday, December 9, 2025
Cross Country Healthcare Inc
7 nominees · 3 ballot items.
Three proposals will be voted on at the 2025 annual meeting: (1) election of seven directors, (2) ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the 2025 fiscal year, and (3) advisory (say-on-pay) vote to approve compensation of named executive officers for 2024.
Market cap
$428M
1Y TSR
+1.9%
Board grade
C
Record date
Oct 14, 2025
Filing
DEF 14A
Meeting concluded · Dec 9, 2025
Follow how the vote landed and what changed on Cross Country Healthcare Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of seven director nominees
ManagementBoard: FORTo elect seven director nominees to serve for a one-year term
- 2
Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025
ManagementBoard: FORTo ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025
- 3
Non-Binding Advisory Vote to Approve Compensation of Our Named Executive Officers
ManagementBoard: FORTo approve, on a non-binding, advisory basis, the compensation paid to our named executive officers in 2024
Director elections
Nominees on the ballot7
Independent
Tenure on this board
3.5 yrs
Also a director at
Bancorp Inc (TBBK)
Independent
Tenure on this board
3.7 yrs
Independent
Tenure on this board
23.1 yrs
Independent
Tenure on this board
19.2 yrs
Not independent
Tenure on this board
3.7 yrs
Independent
Tenure on this board
6.2 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Boston Partners | 7.6% | 2,470,438 | $23M |
| 2 | DIMENSIONAL FUND ADVISORS LP | 4.7% | 1,523,058 | $14M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 1,369,654 | $13M |
| 4 | BlackRock, Inc. | 3.8% | 1,217,577 | $11M |
| 5 | Sio Capital Management, LLC | 3.4% | 1,098,393 | $10M |
| 6 | Quinn Opportunity Partners LLC | 3.2% | 1,025,620 | $10M |
| 7 | BlackRock, Inc. | 3.1% | 991,008 | $9M |
| 8 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2.9% | 952,125 | $9M |
| 9 | AMERICAN CENTURY COMPANIES INC | 2.9% | 948,128 | $9M |
| 10 | ODDO BHF ASSET MANAGEMENT SAS | 2.9% | 940,000 | $9M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Cross Country Healthcare Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Indaptus Therapeutics IncINDP
Annual meeting·Aug 10, 2026·$287M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$712M
Seer IncSEER
Annual meeting·Jul 28, 2026·$119M
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.6B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.6B
Reference
Frequently asked questions
- When is the Cross Country Healthcare Inc 2025 annual meeting?
- Cross Country Healthcare Inc (CCRN) holds its 2025 annual shareholder meeting on Tuesday, December 9, 2025.
- What is the record date for the Cross Country Healthcare Inc 2025 meeting?
- The record date for the Cross Country Healthcare Inc 2025 meeting is Tuesday, October 14, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Cross Country Healthcare Inc's 2025 meeting?
- The board is presenting 7 director nominees at the Cross Country Healthcare Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Cross Country Healthcare Inc 2025 meeting?
- Shareholders will vote on 3 proposals at the Cross Country Healthcare Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.